Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy

Mona Lisa Alattar, MD, Jorge E. Cortes, Susan O'Brien, MD, Guillermo Garcia-Manero, Stefan Faderl, MD, Farhad Ravandi, MD, Elias Jabbour, Jianqin Shan, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 2749.

https://doi.org/10.1182/blood.V118.21.2749.2749

Published: 2011

Journal Articles

Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,

Farhad Ravandi, MD, Stefan Faderl, MD, Sherry Pierce, RN, BS, Guillermo Garcia-Manero, Mark Brandt, BS, Jianqin Shan, PhD, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Susan o'Brien, Jorge E. Cortes, Hagop M. Kantarjian

Blood (2011) 118 (21): 3569.

https://doi.org/10.1182/blood.V118.21.3569.3569

Published: 2011

Journal Articles

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

Alfonso QuintÀs-Cardama, MD, Hawk Kim, MD, Jianqin Shan, PhD, Elias Jabbour, Stefan Faderl, MD, William G. Wierda, MD, PhD, Farhad Ravandi, MD, Tapan Kadia, Sa A. Wang, MD, Sherry Pierce, RN, BS, Hagop M Kantarjian, Guillermo Garcia-Manero

Blood (2011) 118 (21): 967.

https://doi.org/10.1182/blood.V118.21.967.967

Published: 2011

Journal Articles

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

Farhad Ravandi, MD, Deborah A. Thomas, MD, Susan O'Brien, MD, Rebecca Garris, BSc, Stefan Faderl, MD, Jianqin Shan, PhD, Gautam Borthakur, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Partow Kebriaei, MD, Richard Champlin, MD, Zeev Estrov, Sa A. Wang, MD, Jeffrey L. Jorgensen, MD, PhD, Rajyalakshmi Luthra, PhD, Jorge E. Cortes, Hagop M. Kantarjian

Blood (2011) 118 (21): 1453.

https://doi.org/10.1182/blood.V118.21.1453.1453

Published: 2011

Journal Articles

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

Farhad Ravandi, Jorge Cortes, Stefan Faderl, Susan O'Brien, Guillermo Garcia-Manero, Srdan Verstovsek, Fabio P. S. Santos, Jianqin Shan, Mark Brandt, Marcos de Lima, Sherry Pierce, Hagop Kantarjian

Blood (2010) 116 (26): 5818–5823.

https://doi.org/10.1182/blood-2010-07-296392

Published: 2010

Journal Articles

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

Hagop Kantarjian, Farhad Ravandi, Susan O'Brien, Jorge Cortes, Stefan Faderl, Guillermo Garcia-Manero, Elias Jabbour, William Wierda, Tapan Kadia, Sherry Pierce, Jianqin Shan, Michael Keating, Emil J. Freireich

Blood (2010) 116 (22): 4422–4429.

https://doi.org/10.1182/blood-2010-03-276485

Published: 2010

Includes: Supplemental data

Journal Articles

Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML)

Hagop Kantarjian, MD, Susan O'Brien, MD, Elias Jabbour, MD, Jianqin Shan, PhD, Farhad Ravandi, MD, Tapan Kadia, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD

Blood (2010) 116 (21): 672.

https://doi.org/10.1182/blood.V116.21.672.672

Published: 2010

Journal Articles

Analysis of Outcomes In Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia (CML) Treated with Upfront Tyrosine Kinase Inhibitors (TKI)

Naveen Pemmaraju, MD, Hagop Kantarjian, MD, Jianqin Shan, PhD, Elias Jabbour, MD, Alfonso Quintas-Cardama, MD, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, William G. Wierda, MD, PhD, Susan O'Brien, Jorge E. Cortes, MD

Blood (2010) 116 (21): 1234.

https://doi.org/10.1182/blood.V116.21.1234.1234

Published: 2010

Journal Articles

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

Pamela S. Becker, MD, PhD, Hagop Kantarjian, MD, Frederick R. Appelbaum, MD, Stephen H. Petersdorf, MD, Barry Storer, PhD, Sherry A. Pierce, RN, BS, Jianqin Shan, PhD, Paul C. Hendrie, MD, PhD, John M. Pagel, MD, PhD, Andrei Shustov, MD, Derek L. Stirewalt, MD, Stefan Faderl, MD, Elizabeth Harrington, RN, Elihu H. Estey, MD

Blood (2010) 116 (21): 1065.

https://doi.org/10.1182/blood.V116.21.1065.1065

Published: 2010

Journal Articles

Seven-Year Follow-up Data on Sequential Prospective Trials of Imatinib 400mg Vs 800mg Daily Schedule for Front-Line Treatment of Chronic Myeloid Leukemia (CML).

Naveen Pemmaraju, MD, Hagop Kantarjian, MD, Susan O'Brien, Srdan Verstovsek, MD, PhD, Elias Jabbour, MD, Alfonso Quintas-Cardama, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Jianqin Shan, PhD, Jorge E. Cortes, MD

Blood (2010) 116 (21): 3438.

https://doi.org/10.1182/blood.V116.21.3438.3438

Published: 2010

Journal Articles

Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index

Kiran Naqvi, MD, Maria E Suarez-Almazor, MD, PhD, Sagar Sardesai, MD, Jeong Oh, MD, MPH, Carlos Vigil, MD, Sherry Pierce, RN, BS, Xiudong Lei, PhD, Jianqin Shan, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2010) 116 (21): 605.

https://doi.org/10.1182/blood.V116.21.605.605

Published: 2010

Journal Articles

Current Leukemia Free Survival After Tyrosine Kinase Inhibitor (TKI) for Chronic Myeloid Leukemia (CML): A New Method That Accounts for Restoring Response with Sequential TKI.

Aref Al-Kali, MD, Hagop Kantarjian, MD, Jianqin Shan, William G. Wierda, M.D., Ph.D, Gautam Borthakur, MD, Zeev Estrov, MD, Srdan Verstovsek, MD, PhD, Susan O'Brien, M.D., Jorge Cortes, MD

Blood (2009) 114 (22): 2197.

https://doi.org/10.1182/blood.V114.22.2197.2197

Published: 2009

Journal Articles

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

Wei-gang Tong, MD, PhD, Tapan Kadia, MD, Gautam Borthakur, MD, Elias Jabbour, MD, Sherry Pierce, RN, Jianqin Shan, PhD, Jorge Cortes-Franco, MD, Farhad Ravandi, MD, William Wierda, MD, PhD, Deborah Thomas, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2009) 114 (22): 3819.

https://doi.org/10.1182/blood.V114.22.3819.3819

Published: 2009

Journal Articles

A Prognostic Model of Therapy-Related Myelodysplastic syndrome .

Hawk Kim, MD, Elias Jabbour, MD, Tapan Kadia, MD, Gautam Borthakur, Sherry Pierce, RN, Jianqin Shan, PhD, Jorge Cortes, MD, Farhad Ravandi, MD, William G Wierda, Zeev Estrov, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD

Blood (2009) 114 (22): 3796.

https://doi.org/10.1182/blood.V114.22.3796.3796

Published: 2009

Journal Articles

Causes of Death for Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Imatinib.

Andrea Renata Dean, MD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Mary Beth Rios, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Jianqin Shan, Ph.D, Jorge Cortes, MD

Blood (2009) 114 (22): 4279.

https://doi.org/10.1182/blood.V114.22.4279.4279

Published: 2009

Journal Articles

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

Alfonso Quintás-Cardama, Hagop Kantarjian, Dan Jones, Jianqin Shan, Gautam Borthakur, Deborah Thomas, Steven Kornblau, Susan O'Brien, Jorge Cortes

Blood (2009) 113 (25): 6315–6321.

https://doi.org/10.1182/blood-2008-07-166694

Published: 2009

Journal Articles

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase

Carmen Fava, Hagop M. Kantarjian, Elias Jabbour, Susan O'Brien, Nitin Jain, Mary Beth Rios, Guillermo Garcia-Manero, Farhad Ravandi, Srdan Verstovsek, Gautam Borthakur, Jianqin Shan, Jorge Cortes

Blood (2009) 113 (21): 5058–5063.

https://doi.org/10.1182/blood-2008-10-184960

Published: 2009

Journal Articles

Significance of Rising Levels of Minimal Residual Disease in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+ CML) in Complete Cytogenetic Response (CGCR)

Hagop M Kantarjian, Jianqin Shan, Dan Jones, Susan O’Brien, Mary Beth Rios, Elias Jabbour, Jorge Cortes

Blood (2008) 112 (11): 445.

https://doi.org/10.1182/blood.V112.11.445.445

Published: 2008

Journal Articles

Patients with Chronic Myeloid Leukemia with Variant Philadelphia Chromosome (Ph) Translocations Have a Similar Outcome as Those with Classic Ph When Treated with Imatinib or 2 nd Generation TKI

Nicolas Batty, Hagop Kantarjian, Gautam Borthakur, Farhad Ravandi, Susan O’Brien, Zeev Estrov, Jianqin Shan, Srdan Verstovsek, Jorge Cortes

Blood (2008) 112 (11): 3228.

https://doi.org/10.1182/blood.V112.11.3228.3228

Published: 2008

Journal Articles

Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)

Hagop M Kantarjian, Susan O’Brien, Farhad Ravandi, Jorge Cortes, Jianqin Shan, John M. Bennett, MD, Alan F. List, MD, Pierre Fenaux, MD, PhD, Guillermo Garcia-Manero

Blood (2008) 112 (11): 635.

https://doi.org/10.1182/blood.V112.11.635.635

Published: 2008

NARROW

Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy

Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML)

Analysis of Outcomes In Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia (CML) Treated with Upfront Tyrosine Kinase Inhibitors (TKI)

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

Seven-Year Follow-up Data on Sequential Prospective Trials of Imatinib 400mg Vs 800mg Daily Schedule for Front-Line Treatment of Chronic Myeloid Leukemia (CML).

Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index

Current Leukemia Free Survival After Tyrosine Kinase Inhibitor (TKI) for Chronic Myeloid Leukemia (CML): A New Method That Accounts for Restoring Response with Sequential TKI.

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

A Prognostic Model of Therapy-Related Myelodysplastic syndrome .

Causes of Death for Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Imatinib.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase

Significance of Rising Levels of Minimal Residual Disease in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+ CML) in Complete Cytogenetic Response (CGCR)

Patients with Chronic Myeloid Leukemia with Variant Philadelphia Chromosome (Ph) Translocations Have a Similar Outcome as Those with Classic Ph When Treated with Imatinib or 2 nd Generation TKI

Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only